Dr Jennifer Leeds

Dr. Leeds is an Executive Director and Head of Antibacterial Discovery within the Infectious Diseases Area of the Novartis Institutes for Biomedical Research where she is responsible for the strategy and execution of the new antibacterial portfolio from target discovery through clinical validation.  Dr. Leeds is an expert in bacterial genetics and physiology, antibacterial mechanisms of action and resistance, drug discovery, clinical microbiology, and clinical development.  Dr. Leeds co-invented and co-led the international discovery project team for the novel antibacterial LFF571, which demonstrated safety and efficacy in humans for the treatment of C. difficile infection. 

Dr. Leeds received her Bachelor of Science degree in Microbiology from Cornell University, and her Ph.D. in Medical Microbiology and Immunology from the University of Wisconsin-Madison.  Prior to joining the pharmaceutical industry in 2001, Dr. Leeds was a postdoctoral fellow in Microbiology and Molecular Genetics at Harvard Medical School, where she trained in the laboratory of Dr. Jonathan Beckwith.

Session 2: Antimicrobial drug discovery I
Monday 3 April
Chair: Dr Mark Blaskovich

Supported By